

Controversies in thyroid cancer management

Chair: Dagmar Führer and Johannes W Smit

PROGRAMM

08:00 - 08:30	Registration and coffee
08:30 – 08:35	Presidential address and Introduction Dagmar Führer, President of ETA-CRN (Germany)
08:35 – 10:15	Up-to-date diagnosis of differentiated thyroid cancer Molecular diagnostics in FNA: gene expression or mutation based approach?:
08:35 – 09:05	For gene expression (AFIRMA) classifier: Richard T. Kloos (USA)
09:05 – 09:35	For mutation based approach: Markus Eszlinger (Germany)
09:35 – 10:00	Discovering DTC recurrence by conventional vs. highly sensitive Tg assays: L. Giovanella (Switzerland)
10:00 – 10:15	Discussion
10:15 – 11:30	What is the present role of molecular pathology? Should BRAF positive cancers be managed differently?:
10:15 – 10:45	For: Michael Mingzhao Xing (USA)
10:45 – 11:15	Against: Laura Fugazzola (Italy)
11:15 – 11:30	Discussion
11:45 – 13:00	Cardiovascular events and TSH suppression
11:45 – 12:15	Do the patients with thyroid cancer die from cardiovascular events, not disease? Esther Klein Hesselink, Thera Links (The Netherlands)
12:15 – 12:45	What are the present indications for L-thyroxine TSH-suppressive therapy in thyroid cancer patients? Johannes W Smit (The Netherlands)
12:45 – 13:00	Discussion
13:00 – 13:30	Approach to complex issues in Thyroid Cancer
13:00 – 13:15	EUROCRINE Project – the European Register of Rare Endocrine Tumors: Marcin Barczynski (Poland)
13:15 – 13:30	Other initiatives: Dagmar Führer
13:30 – 13:45	General comments and any other business
